Chromatography/mass spectrometry-based biomarkers in the field of obstructive sleep apnea

Medicine (United States)

Volumn 94, Issue 40, 2015, Pages

  Xu, Huajun ^a,b   Zheng, Xiaojiao ^a,b   Jia, Wei ^b   Yin, Shankai ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 3 NITROTYROSINE; ALBUMIN; AMINO ACID; AMINO ACID DERIVATIVE; ANANDAMIDE; BIOLOGICAL MARKER; CARBON MONOXIDE; CAROTENOID; COLLAGEN; DOPAMINE; FATTY ACID; FIBRINOGEN; GELSOLIN; HOMOCYSTEINE; HOMOVANILLIC ACID; ICOSANOID; IMMUNOGLOBULIN; ISOPROSTANE DERIVATIVE; LEUKOTRIENE E4; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; NORADRENALIN; NORMETADRENALIN; PEPTIDE; PERLECAN; PHOSPHATIDYLCHOLINE; PHOSPHOETHANOLAMINE; PHOSPHOSERINE; TOCOPHEROL; CATECHOLAMINE;

CHROMATOGRAPHY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; PRIORITY JOURNAL; PROTEOMICS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; BLOOD; LIPID METABOLISM; MASS FRAGMENTOGRAPHY; METABOLISM; OXIDATIVE STRESS; SLEEP APNEA, OBSTRUCTIVE; URINE;

AMINO ACIDS; BIOMARKERS; CATECHOLAMINES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIPID METABOLISM; OXIDATIVE STRESS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84944097227     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001541     Document Type: Review

References (85)

1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230-1235.
2. Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;117:1006-1014.
3. Strollo PJ Jr, Rogers RM. Obstructive sleep apnea. N Engl J Med. 1996;334:99-104.
4. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc. 2008;5:207-217.
5. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000;283:1829-1836.
6. Dyken ME, Somers VK, Yamada T, et al. Investigating the relationship between stroke and obstructive sleep apnea. Stroke. 1996;27:401-407.
7. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003;290:1906-1914.
8. Kendzerska T, Gershon AS, Hawker G, et al. Obstructive sleep apnea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med. 2014;190:218-225.
9. Christensen AS, Clark A, Salo P, et al. Symptoms of sleep disordered breathing and risk of cancer: a prospective cohort study. Sleep. 2013;36:1429-1435.
10. Gilat H, Vinker S, Buda I, et al. Obstructive sleep apnea and cardiovascular comorbidities: a large epidemiologic study. Medicine. 2014;93:e45.
11. Xie W, Zheng F, Song X. Obstructive sleep apnea and serious adverse outcomes in patients with cardiovascular or cerebrovascular disease: a PRISMA-compliant systematic review and meta-analysis. Medicine. 2014;93:e336.
12. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med. 2009;6:e1000132.
13. Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012;8:597-619.
14. Montesi SB, Bajwa EK, Malhotra A. Biomarkers of sleep apnea. Chest. 2012;142:239-245.
15. Arnardottir ES, Mackiewicz M, Gislason T, et al. Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep. 2009;32:447-470.
16. Tan HL, Kheirandish-Gozal L, Gozal D. The promise of translational and personalised approaches for paediatric obstructive sleep apnoea: an "Omics" perspective. Thorax. 2014;69:474-480.
17. Zhao YY. Metabolomics in chronic kidney disease. Clin Chim Acta. 2013;422:59-69.
18. Konvalinka A, Scholey JW, Diamandis EP. Searching for new biomarkers of renal diseases through proteomics. Clin Chem. 2012;58:353-365.
19. Murri M, Insenser M, Escobar-Morreale HF. Metabolomics in polycystic ovary syndrome. Clin Chim Acta. 2014;429:181-188.
20. Insenser M, Escobar-Morreale HF. Proteomics and polycystic ovary syndrome. Expert Rev Proteomics. 2013;10:435-447.
21. Abbassi-Ghadi N, Kumar S, Huang J, et al. Metabolomic profiling of oesophago-gastric cancer: a systematic review. Eur J Cancer. 2013;49:3625-3637.
22. Shukla HD, Vaitiekunas P, Cotter RJ. Advances in membrane proteomics and cancer biomarker discovery: current status and future perspective. Proteomics. 2012;12:3085-3104.
23. Zhang AH, Qiu S, Xu HY, et al. Metabolomics in diabetes. Clin Chim Acta. 2014;429:106-110.
24. Sundsten T, Ortsäter H. Proteomics in diabetes research. Mol Cell Endocrinol. 2009;297:93-103.
25. Snowden S, Dahlén SE, Wheelock CE. Application of metabolomics approaches to the study of respiratory diseases. Bioanalysis. 2012;4:2265-2290.
26. O'Neil SE, Lundbäck B, Lötvall J. Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities. J Proteomics. 2011;75:192-201.
27. Wilkins MR, Pasquali C, Appel RD, et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y). 1996;14:61-65.
28. Xie G, Li X, Li H, et al. Toward personalized nutrition: comprehensive phytoprofiling and metabotyping. J Proteome Res. 2013;12:1547-1559.
29. Ferrarini A, Rupérez FJ, Erazo M, et al. Fingerprinting-based metabolomic approach with LC-MS to sleep apnea and hypopnea syndrome: a pilot study. Electrophoresis. 2013;34:2873-2881.
30. Krishna J, Shah ZA, Merchant M, et al. Urinary protein expression patterns in children with sleep-disordered breathing: preliminary findings. Sleep Med. 2006;7:221-227.
31. Shah ZA, Jortani SA, Tauman R, et al. Serum proteomic patterns associated with sleep-disordered breathing in children. Pediatr Res. 2006;59:466-470.
32. Gozal D, Jortani S, Snow AB, et al. Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in pediatric obstructive sleep apnea. Am J Respir Crit Care Med. 2009;180:1253-1261.
33. Becker L, Kheirandish-Gozal L, Peris E, et al. Contextualised urinary biomarker analysis facilitates diagnosis of paediatric obstructive sleep apnoea. Sleep Med. 2014;15:541-549.
34. Jurado-Gamez B, Gomez-Chaparro JL, Muñoz-Calero M, et al. Serum proteomic changes in adults with obstructive sleep apnoea. J Sleep Res. 2012;21:139-146.
35. Seetho IW, Siwy J, Albalat A, et al. Urinary proteomics in obstructive sleep apnoea and obesity. Eur J Clin Invest. 2014;44:1104-1115.
36. Zheng H, Li R, Zhang J, et al. Salivary biomarkers indicate obstructive sleep apnea patients with cardiovascular diseases. Sci Rep. 2014;4:7046.
37. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.
38. Papandreou C. Gluteal adipose tissue fatty acids and sleep quality parameters in obese adults with OSAS. Sleep Breath. 2013;17:1315-1317.
39. Papandreou C, Schiza SE, Tsibinos G, et al. Gluteal adipose-tissue polyunsaturated fatty-acids profiles and depressive symptoms in obese adults with obstructive sleep apnea hypopnea syndrome: a cross-sectional study. Pharmacol Biochem Behav. 2011;98:316-319.
40. Tang S, Machaalani R, Kashem MA, et al. Intermittent hypercapnic hypoxia induced protein changes in the piglet hippocampus identified by MALDI-TOF-MS. Neurochem Res. 2009;34:2215-2225.
41. Klein JB, Gozal D, Pierce WM, et al. Proteomic identification of a novel protein regulated in CA1 and CA3 hippocampal regions during intermittent hypoxia. Respir Physiol Neurobiol. 2003;136:91-103.
42. Thongboonkerd V, Gozal E, Sachleben LR Jr et al. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem. 2002;277:34708-34716.
43. Snow A, Gozal D, Valdes R, et al. Urinary proteins for the diagnosis of obstructive sleep apnea syndrome. Methods Mol Biol. 2010;641:223-241.
44. Kawai M, Kirkness JP, Yamamura S, et al. Increased phosphatidyl-choline concentration in saliva reduces surface tension and improves airway patency in obstructive sleep apnoea. J Oral Rehabil. 2013;40:758-766.
45. Engeli S, Blüher M, Jumpertz R, et al. Circulating anandamide and blood pressure in patients with obstructive sleep apnea. J Hypertens. 2012;30:2345-2351.
46. Ezzedini R, Darabi M, Ghasemi B, et al. Tissue fatty acid composition in obstructive sleep apnea and recurrent tonsillitis. Int J Pediatr Otorhinolaryngol. 2013;77:1008-1012.
47. Papandreou C. Independent associations between fatty acids and sleep quality among obese patients with obstructive sleep apnoea syndrome. J Sleep Res. 2013;22:569-572.
48. Fletcher EC, Miller J, Schaaf JW, et al. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep. 1987;10:35-44.
49. Findley LJ, Boykin M, Fallon T, et al. Plasma adenosine and hypoxemia in patients with sleep apnea. J Appl Physiol. 1988;64:556-561.
50. Paci A, Marrone O, Lenzi S, et al. Endogenous digitalis like factors in obstructive sleep apnea. Hypertens Res. 2000;23(Suppl):S87-S91.
51. O'Driscoll DM, Horne RS, Davey MJ, et al. Increased sympathetic activity in children with obstructive sleep apnea: cardiovascular implications. Sleep Med. 2011;12:483-488.
52. Paik MJ, Kim DK, Nguyen DT, et al. Correlation of daytime sleepiness with urine metabolites in patients with obstructive sleep apnea. Sleep Breath. 2014;18:517-523.
53. Gislason T, Hedner J, Terenius L, et al. Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients. Am Rev Respir Dis. 1992;146:784-786.
54. Grunstein RR, Stewart DA, Lloyd H, et al. Acute withdrawal of nasal CPAP in obstructive sleep apnea does not cause a rise in stress hormones. Sleep. 1996;19:774-782.
55. Minemura H, Akashiba T, Yamamoto H, et al. Acute effects of nasal continuous positive airway pressure on 24-hour blood pressure and catecholamines in patients with obstructive sleep apnea. Intern Med. 1998;37:1009-1013.
56. Monneret D, Tamisier R, Ducros V, et al. The impact of obstructive sleep apnea on homocysteine and carotid remodeling in metabolic syndrome. Respir Physiol Neurobiol. 2012;180:298-304.
57. Jordan W, Berger C, Cohrs S, et al. CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm. 2004;111:683-689.
58. Ozkan Y, Firat H, Simşek B, et al. Circulating nitric oxide (NO), asymmetric dimethylarginine (ADMA), homocysteine, and oxidative status in obstructive sleep apnea-hypopnea syndrome (OSAHS). Sleep Breath. 2008;12:149-154.
59. Svatikova A, Wolk R, Wang HH, et al. Circulating free nitrotyrosine in obstructive sleep apnea. Am J Physiol Regul Integr Comp Physiol. 2004;287:R284-R287.
60. Monneret D, Pepin JL, Godin-Ribuot D, et al. Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima-media thickness in nonobese sleep apnea patients. Free Radic Biol Med. 2010;48:619-625.
61. Dikmenoglu N, Ciftçi B, Ileri E, et al. Erythrocyte deformability, plasma viscosity and oxidative status in patients with severe obstructive sleep apnea syndrome. Sleep Med. 2006;7:255-261.
62. Montgomery-Downs HE, Krishna J, Roberts LJ, et al. Urinary F2-isoprostane metabolite levels in children with sleep-disordered breathing. Sleep Breath. 2006;10:211-215.
63. Stanke-Labesque F, Bäck M, Lefebvre B, et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol. 2009;124:364-370370.e361-362.
64. Day RM, Matus IA, Suzuki YJ, et al. Plasma levels of retinoids, carotenoids and tocopherols in patients with mild obstructive sleep apnoea. Respirology. 2009;14:1134-1142.
65. Kobayashi M, Miyazawa N, Takeno M, et al. Circulating carbon monoxide level is elevated after sleep in patients with obstructive sleep apnea. Chest. 2008;134:904-910.
66. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26:51-78.
67. Shushan B. A review of clinical diagnostic applications of liquid chromatography-tandem mass spectrometry. Mass Spectrom Rev. 2010;29:930-944.
68. Rankin NJ, Preiss D, Welsh P, et al. The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis. 2014;237:287-300.
69. Putri SP, Yamamoto S, Tsugawa H, et al. Current metabolomics: technological advances. J Biosci Bioeng. 2013;116:9-16.
70. Yin P, Xu G. Current state-of-the-art of nontargeted metabolomics based on liquid chromatography-mass spectrometry with special emphasis in clinical applications. J Chromatogr A. 2014;1374:1-13.
71. Chen CF, Chen LW, Chien CT, et al. Renal kallikrein in chronic hypoxic rats. Clin Exp Pharmacol Physiol. 1996;23:819-824.
72. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959-2964.
73. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357-366.
74. Jullian-Desayes I, Joyeux-Faure M, Tamisier R, et al. Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: a systematic review from sham CPAP randomized controlled trials. Sleep Med Rev. 2015;21:23-38.
75. Chen X, Niu X, Xiao Y, et al. Effect of continuous positive airway pressure on homocysteine levels in patients with obstructive sleep apnea: a meta-analysis. Sleep Breath. 2014;18:687-694.
76. Niu X, Chen X, Xiao Y, et al. The differences in homocysteine level between obstructive sleep apnea patients and controls: a meta-analysis. PLoS ONE. 2014;9:e95794.
77. Archontogeorgis K, Nena E, Papanas N, et al. Biomarkers to improve diagnosis and monitoring of obstructive sleep apnea syndrome: current status and future perspectives. Pulm Med. 2014;2014:930535.
78. Yan W, Byrd GD, Ogden MW. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J Lipid Res. 2007;48:1607-1617.
79. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262-1267.
80. Xie G, Zhang S, Zheng X, et al. Metabolomics approaches for characterizing metabolic interactions between host and its commensal microbes. Electrophoresis. 2013;34:2787-2798.
81. Moreno-Indias I, Torres M, Montserrat JM, et al. Intermittent hypoxia alters gut microbiota diversity in a mouse model of sleep apnoea. Eur Respir J. 2014[Epub ahead of print].
82. Carreras A, Leone V, Peris E, et al. Sleep fragmentation alters gut microbiota: potential association with metabolic alterations in mice. Am J Respir Crit Care Med. 2014;189:2414.
83. Kheirandish-Gozal L, Peris E, Wang Y, et al. Lipopolysaccharide-binding protein plasma levels in children: effects of obstructive sleep apnea and obesity. J Clin Endocrinol Metab. 2014;99:656-663.
84. Cani PD, Geurts L, Matamoros S, et al. Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond. Diabetes Metab. 2014;40:246-257.
85. Cani PD. Crosstalk between the gut microbiota and the endocanna-binoid system: impact on the gut barrier function and the adipose tissue. Clin Microbiol Infect. 2012;18(Suppl 4):50-53.